Hidradenitis suppurativa (HS) shows an unexpected pattern in a new claims-data analysis: the condition's burden appears split evenly between the sexes, while care access skews sharply by geography, with rural patients falling behind their urban counterparts.

That pairing of findings — sex parity alongside a rural care gap — comes from an analysis of insurance claims published by Dermatology Times. It's a combination worth pausing on, because both cut against older assumptions about who gets HS and who actually reaches a dermatologist for it.

Why sex parity matters here

HS has long been discussed with a heavy skew toward female patients, and clinical cohorts have often reflected that. But claims data captures a broader, less filtered population than referral centers do — people coded and billed across primary care, urgent care and dermatology. When a claims analysis lands on something close to parity between men and women, it raises a practical question: are we under-recognizing HS in male patients who never make it into specialty cohorts?

Claims data has limits, of course. Coding accuracy, plan coverage and patient turnover all shape what the numbers show. But as a population-level snapshot, parity is a signal clinicians can act on — it argues against treating HS as a predominantly female diagnosis when triaging nodules, abscesses and recurrent ingrown-type lesions in men.

What does the rural gap change in practice?

The second finding is the access story. Rural patients with HS face a measurable disadvantage in reaching care, according to the claims analysis. Dermatology is already one of the scarcest specialties in rural America; layer a chronic, stigmatizing, painful condition like HS on top and the gap compounds.

The practical consequences are concrete:

• Delayed diagnosis, which for HS typically means years of progressing disease before specialty care
• More emergency-department and urgent-care visits for acute flares instead of planned management
• Less access to the biologics and surgical options that define modern HS treatment
• Higher lifetime disease burden in exactly the population least equipped to manage it

For practices in mixed urban–rural catchments, the claims findings argue for lower referral thresholds and for telehealth follow-up models that keep rural HS patients in active management rather than episodic crisis care.

The bigger picture on HS epidemiology

HS remains an underdiagnosed condition across the board, with average diagnostic delays measured in years, not months. Claims analyses like this one matter because they sidestep the selection bias of clinic-based studies — they see the insured population as it actually moves through the system.

Sex parity in that lens suggests the true epidemiology of HS may be broader than specialty registries imply. The rural gap suggests the binding constraint isn't recognition alone — it's geography and workforce.

Neither finding changes a guideline tomorrow. But together they sharpen where the field should look next: screening conversations in male patients who present with recurrent boils, and access infrastructure for patients an hour or more from the nearest dermatology chair. As claims datasets grow richer, expect sharper quantification of both the parity question and the rural gap — and with it, a stronger case for HS-specific outreach in the populations this analysis says the system is missing.